Myeloproliferative Disorder Clinical Trial
Official title:
Aquagenic Pruritus Among Patients With Myeloproliferative Syndromes (in English) Prurit Aquagénique Dans Les SYndromes MyéloProLifEratifs (in French)
Description of the characteristics of aquagenic pruritus expressed by patients suffering from
myeloproliferative neoplasms.
Prospective work based on the distribution of a dedicated questionnaire.
Patients with myeloproliferative neoplasms identified and followed in our Institution (Brest
University Hospital). Patients could be followed for polycythemia vera or essential
thrombocythemia or myelofibrosis.
Distribution of the questionnaire to each patients with myeloproliferative neoplasms (treated
or not) suffering from aquagenic pruritus.
Analyse of each characteristic of the aquagenic pruritus by a statistician and publication at
the end.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT06246006 -
Functional Characterization of Thrombopoietin/cMPL Receptor Mutations in Myeloproliferative Neoplasia
|
||
| Completed |
NCT03907436 -
The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase
|
N/A | |
| Completed |
NCT03734601 -
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
|
Phase 2 | |
| Completed |
NCT00683046 -
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
|
Phase 2 | |
| Completed |
NCT03149055 -
Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)
|
Phase 2 | |
| Completed |
NCT01866839 -
Preventing Stem Cell Transplant Complications With a Blood Separator Machine
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05884333 -
Cord Blood Transplant in Adults With Blood Cancers
|
Phase 2 | |
| Completed |
NCT00588666 -
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT03480360 -
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
|
Phase 3 | |
| Completed |
NCT00539695 -
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD
|
Phase 2 | |
| Recruiting |
NCT03869476 -
Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.
|
N/A | |
| Completed |
NCT00175838 -
Primary Thrombocythaemia 1 Trial
|
N/A | |
| Active, not recruiting |
NCT03434730 -
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
|
Phase 2 | |
| Recruiting |
NCT03852407 -
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
|
Phase 2 | |
| Completed |
NCT01499147 -
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
|
N/A | |
| Completed |
NCT00533923 -
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
|
Phase 2 | |
| Active, not recruiting |
NCT04473911 -
Haplo Peripheral Blood Sct In GVHD Prevention
|
Phase 1 | |
| Completed |
NCT00909467 -
Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative Diseases
|
N/A | |
| Completed |
NCT00687414 -
Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders
|
||
| Recruiting |
NCT03808805 -
Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms
|
Phase 3 |